See more : Nucleus Software Exports Limited (NUCLEUS.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Genprex, Inc. (GNPX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genprex, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- FAT Brands Inc. (FAT) Income Statement Analysis – Financial Results
- Windtree Therapeutics, Inc. (WINTW) Income Statement Analysis – Financial Results
- Zhejiang Meili High Technology Co., Ltd. (300611.SZ) Income Statement Analysis – Financial Results
- Centaur Media Plc (CAU.L) Income Statement Analysis – Financial Results
- Hanpin Electron Co., Ltd. (2488.TW) Income Statement Analysis – Financial Results
Genprex, Inc. (GNPX)
About Genprex, Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 15.00K | 23.83M | 22.53K | 22.78K | 13.07K | 5.89K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -15.00K | -23.83M | -22.53K | -22.78K | -13.07K | -5.89K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 17.62M | 11.51M | 8.61M | 7.30M | 1.97M | 971.43K | 289.93K | 354.88K | 201.96K |
| General & Administrative | 13.44M | 12.30M | 10.97M | 10.64M | 8.70M | 11.39M | 3.02M | 3.78M | 865.70K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.44M | 12.30M | 10.97M | 10.64M | 8.70M | 11.39M | 3.02M | 3.78M | 865.70K |
| Other Expenses | 0.00 | 25.58K | 22.53K | 22.78K | 13.07K | 5.89K | 3.24K | 0.00 | 0.00 |
| Operating Expenses | 31.06M | 23.83M | 19.60M | 17.96M | 10.68M | 12.36M | 3.31M | 4.13M | 1.07M |
| Cost & Expenses | 31.08M | 23.83M | 19.60M | 17.96M | 10.68M | 12.36M | 3.31M | 4.13M | 1.07M |
| Interest Income | 215.11K | 90.10K | 5.13K | 18.81K | 27.91K | 29.18K | 80.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.98K | 1.89K | 0.00 | 0.00 |
| Depreciation & Amortization | 15.00K | 25.58K | 22.53K | 22.78K | 13.07K | 5.89K | 3.24K | 862.00 | 2.06K |
| EBITDA | -31.06M | -23.81M | -20.65M | -17.94M | -10.64M | -12.33M | -3.31M | -4.13M | -1.07M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -31.08M | -23.83M | -19.60M | -17.96M | -10.68M | -12.36M | -3.31M | -4.13M | -1.07M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 215.11K | 90.10K | 5.13K | 18.81K | 27.90K | -8.80K | -1.81K | 0.00 | 0.00 |
| Income Before Tax | -30.86M | -23.74M | -19.60M | -17.94M | -10.65M | -12.37M | -3.31M | -4.13M | -1.07M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 5.72M | -5.13K | -18.81K | -130.89K | 29.18K | 80.00 | 0.00 | 0.00 |
| Net Income | -30.86M | -29.46M | -19.59M | -17.92M | -10.65M | -12.37M | -3.31M | -4.13M | -1.07M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -22.58 | -24.59 | -16.64 | -20.18 | -26.64 | -35.97 | -11.55 | -15.30 | -23.25 |
| EPS Diluted | -22.56 | -24.58 | -16.64 | -20.18 | -26.59 | -35.94 | -11.53 | -15.26 | -22.93 |
| Weighted Avg Shares Out | 1.37M | 1.20M | 1.18M | 888.00K | 400.00K | 344.00K | 287.00K | 270.00K | 46.00K |
| Weighted Avg Shares Out (Dil) | 1.37M | 1.20M | 1.18M | 888.07K | 400.68K | 344.28K | 287.50K | 270.87K | 46.66K |
Genprex secures higher dose approval for REQORSA in combination with Tagrisso Phase 1 clinical trial
Genprex, Inc. (NASDAQ:GNPX) announced that the Safety Review Committee (SRC) has approved a continuation of the Acclaim-1 Phase 1/2 clinical trial of the company's lead drug candidate REQORSA in combination with Tagrisso (osimertinib) to treat late-stage non-small cell lung cancer...
Genprex to Present at Upcoming Investor Conference in May 2022
Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 19, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with...
Genprex announces opening of patient enrollment for its Acclaim-2 clinical trial
Genprex Inc said it has opened patient enrollment for its Acclaim-2 clinical trial evaluating the company's lead drug candidate, REQORSA Immunogene Therapy. Acclaim-2 is an open-label, multi-center Phase 1/2 clinical trial evaluating REQORSA Immunogene Therapy in combination with Keytruda (pembrolizumab) in patients with...
4 ‘Must Watch' Penny Stocks Making Big Moves After Latest News
4 names for your penny stocks list this week. The post 4 ‘Must Watch' Penny Stocks Making Big Moves After Latest News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Genprex says preclinical data shows potential for ONCOPREX Nanoparticle Delivery System in treating colon cancer
Genprex Inc announced that its collaborators published positive clinical data for the use of Genprex's ONCOPREX Nanoparticle Delivery System for delivery of a FAS DNA plasmid to treat metastatic colorectal cancer. Published in the journal Cancers, the preclinical study found...
Genprex says it plans to ramp up opening of its Acclaim-1 clinical trial sites
Genprex Inc has announced a plan to accelerate the opening of trial sites for the Acclaim-1 clinical trial, which combines the company's lead product candidate, REQORSA (quaratusugene ozeplasmid) Immunogene Therapy, with AstraZeneca's Tagrisso as a potential innovative treatment for non-small cell...
Genprex's (GNPX) Lead Cancer Drug Gets Second Fast Track Tag
The FDA bestows a Fast Track designation to Genprex's (GNPX) Reqorsa in combination with Keytruda for treating patients with non-small cell lung cancer. This is the second Fast Track tag for Reqorsa.
Genprex Stock (GNPX): Why The Price Surged
The stock price of Genprex Inc (NASDAQ: GNPX) increased by 167.18% in the most recent trading session. This is why it happened.
Genprex up by 130% after receiving FDA fast track designation
Genprex Inc (NASDAQ: GNPX) is a clinical-stage gene therapy organization that concentrates on the development of life-changing gene therapies to treat people with diabetes and cancer. The company announced that it had received FTD (Fast Track Designation) from the Food and...
Genprex stock more than doubles on very heavy volume after FTD granted for cancer treatment
Shares of Genprex Inc. GNPX, +121.37% skyrocketed 121% on massive volume in afternoon trading Monday, after the gene therapy company said its Reqorsa Immunogene Therapy was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration for use...
Source: https://incomestatements.info
Category: Stock Reports